Clinical trials: Hepatitis C
Hepatitis C
3-Year Observational Virology Follow-up Study in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Acting Antivirals
All subjects in this study have previously been in an Idenix HCV study and received study drug for 3 consecutive days. Subjects who had received placebo in a previous Idenix study will not be enrolled in this study.
- Trial name
- NCT01721265
- Volunteers
- 145 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Study of the Impact of Nitazoxanide on Chronic Hepatitis Patients
The main objective of antiviral therapy of patients with chronic hepatitis C (CHC) is the sustained elimination of the hepatitis C virus (HCV).
- Trial name
- NCT01197157
- Testing
- Nitazoxanide
- Where
- Egypt
- Volunteers
- 200 people
- Sponsor
- National Liver Institute, Egypt
Hepatitis C
Prevalence and Screening of Hepatitis C in Belgium in 2015
Hepatitis C is caused by the hepatitis C virus (HCV) that causes inflammation of the liver that can lead to diminished liver function or liver failure.
- Trial name
- NCT02393365
- Testing
- Questionnaire, HCV serology
- Where
- 4 sites in Belgium
- Volunteers
- 10,000 people
- Sponsor
- Brugmann University Hospital
HCV Infection
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
The purpose of this study is to compare the safety, tolerability and effectiveness of the experimental drug GS-9190 when administered for 24 or 48 weeks with peginterferon alfa 2a and ribavirin for the treatment of genotype-1…
- Trial name
- NCT00743795
- Testing
- GS-9190, Peginterferon Alfa 2a, Ribavirin
- Where
- 72 sites in United States, Belgium and 5 more
- Volunteers
- 252 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis C
The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects
A Phase I, Single Center, Randomized, Double-blind, Placebo-controlled, Single \& Multiple Ascending Dose Study to Access the Tolerability and Pharmacokinetics of HEC110114 Tablets in Healthy Adult Subjects
- Trial name
- HEC110114 (NCT03903081)
- Testing
- HEC110114 tablet
- Where
- China
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis C
Alcohol Use Reduction in Methadone Individuals With Hepatitis C Virus(HCV)
The Alcohol Use Reduction in Methadone Individuals with HCV was designed to compare three different types of programs for methadone maintained men and women to determine which of the three programs is most effective for:1)…
- Trial name
- NIAAA (NCT00958763)
- Testing
- Motivational Interviewing, Single - MIS, Motivational Interviewing Group, Usual Care Group - UCG
- Where
- 3 sites in United States
- Volunteers
- 219 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Chronic Hepatitis C
Phase I/II Trial of KRN7000 in Patients With Chronic Hepatitis C Infection
Phase I/II trial of KRN7000 in patients with chronic hepatitis C. Study objectives: To evaluate and compare the safety and tolerability of 3 ascending doses of a-GalCer.
- Trial name
- NCT00352235
- Testing
- KRN7000
- Where
- Netherlands
- Volunteers
- 36 people
- Sponsor
- Foundation for Liver Research
Hepatitis C
PoC-HCV Genedrive Viral Detection Assay Validation Study
The principal objective is to assess the diagnostic accuracy of the PoC assay (Genedrive, Epistem) to detect HCV RNA against the reference standard of commercial real-time polymerase chain reaction (RT-PCR) assay (RealTime HCV…
- Trial name
- NCT02992184
- Testing
- HCV RNA detection with Genedrive assay, HCV RNA detection with RealTime HCV
- Volunteers
- 417 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Chronic Hepatitis C
Exploration of Chronic Hepatitis C Infection Receiving 24-week Interferon-α With Ribavirin Treatments
The aims of this three-year study are to explore symptom experience and its related factors for the patients with chronic hepatitis C Infection receiving interferon-α with ribavirin for 24 weeks and further to predict the…
- Trial name
- NCT01178749
- Where
- Taiwan
- Volunteers
- 390 people
- Sponsor
- National Taiwan University Hospital
Opioid-related Disorders, HIV Infections
Project BEST: Buprenorphine Entry Into Substance Abuse Treatment
Project BEST is a clinical project funded by the Substance Abuse and Mental Health Services Administration (SAMHSA) to increase treatment to opiate dependent patients with mental illness in New Haven, CT and to prospectively…
- Conditions
- Opioid-related Disorders, HIV Infections, Hepatitis C, Chronic, Depression
- Trial name
- NCT02583243
- Testing
- MET/CBT based individualized counseling, Buprenorphine
- Where
- United States
- Volunteers
- 209 people
- Sponsor
- Yale University
Hepatitis C
Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients
Chronic active hepatitis C viral infections are difficult to treat: current drug therapies can result in severe side effects that some patients will not tolerate.
- Trial name
- NCT00229749
- Testing
- AVI-4065 Injection
- Volunteers
- 80 people
- Sponsor
- Sarepta Therapeutics, Inc.
Hepatitis C, Chronic
Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients
The purpose of this study was to investigate antiviral activity, safety and pharmacokinetics of 5 days of monotherapy with BI 207127 in HCV genotype 1 (GT1) infected patients.
- Trial name
- NCT02176525
- Testing
- BI 207127 NA
- Volunteers
- 75 people
- Sponsor
- Boehringer Ingelheim
Chronic Hepatitis C Infection
Follow up of IFN Vs DAAs HCV SVR (IFDACS Study)
The study is designed to provide long term clinical and virologic follow up in subjects infected with hepatitis C virus (HCV) who received interferon-based therapy or direct-acting antiviral agents (DAAs)-based therapy.
- Trial name
- NCT02578693
- Where
- 3 sites in China, Japan
- Volunteers
- 1,210 people
- Sponsor
- Humanity and Health Research Centre
Chronic Hepatitis c
Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population
A single Center, Prospective Phase IV, Open-Label, Controlled, Randomized Trial comparing the efficacy, safety, and tolerability of Quadritherapy regimen (Reiferon Retard® , Ribavirin , Nitazoxanide and Alfacalcidol (Bon-One ® )…
- Trial name
- Quadritherapy (NCT01896609)
- Testing
- Reiferon Retard in Arm 1, Bon one in Arm 3, Xerovirinc in Arm 2
- Where
- Egypt
- Volunteers
- 300 people
- Sponsor
- MinaPharm Pharmaceuticals
Chronic Hepatitis C
Pilot Comparison of Standard Antiviral Therapy With and Without 12 Weeks of Betaine in Genotype 1 Naive Patients
The primary purpose of the study is to compare the safety and effectiveness of standard treatment for chronic hepatitis C using peginterferon alpha-2a (Pegasys) and ribavirin (Copegus) to those same medications plus a dietary…
- Trial name
- NCT00571714
- Testing
- Peginterferon alpha-2a and ribavirin, Peginterferon alpha-2a , ribavirin and betaine
- Sponsor
- University of Nebraska
Chronic Hepatitis C Infection
Switching Regimen in Treating Cirrhotic HCV GT1b Subjects
This is a prospective, randomized study to evaluate the efficacy and safety of switching treatment from Peg-interferon and Ribavirin to direct-acting antiviral agents in Chinese with CHC genotype 1b infection, who are…
- Trial name
- SWITCH-1 (NCT02583685)
- Testing
- PR4 + LDV/SOF + ASV 4 wk, PR4 + LDV/SOF + SMV 4 wk, PR4 + LDV/SOF + ASV 6 wk
- Where
- 2 sites in China
- Volunteers
- 138 people
- Sponsor
- Humanity and Health Research Centre
Hepatitis C, Chronic
Efficacy and Safety of 24 vs 48 Weeks of Pegetron® (Peginterferon Alfa-2b + Ribavirin) in Naïve Genotype 1 Hepatitis C (Study P05016)(TERMINATED)
This is a Phase IIIB randomized, controlled, multi-centre, open-label study of 24 versus 48 weeks therapy with Pegetron® (peginterferon alfa-2b + ribavirin) at standard doses in naïve Hepatitis C Virus (HCV) genotype 1 high viral…
- Trial name
- NCT00423800
- Testing
- Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Meningococcal Meninigitis, Serogroup C
Follow-up Study on the Antibody Response to Hepatitis B, Acellular Pertussis Toxin and Inactivated Poliovirus Antigens 1 Month After the 4th Hexavac® Vaccination in Healthy Children, Who Participated in NeisVac-C Study 216
The primary aim of the study is to show that the antibody response to hepatitis B, acellular pertussis toxin and inactivated poliovirus antigens after the 4th vaccination with Hexavac® is not influenced by the concomitant…
- Trial name
- NCT00161941
- Where
- 11 sites in Austria, Germany
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- Pfizer
HCV Coinfection
Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B
HCV infection is one of the most prevalent etiologies for liver cirrhosis and hepatocellular carcinoma. HCV is highly heterogeneous, with seven confirmed major genotypes.
- Trial name
- NCT03050905
- Testing
- VEKIRAX, EXVIERA
- Where
- Israel
- Volunteers
- 7 people
- Sponsor
- HaEmek Medical Center, Israel
Hepatitis C, Chronic, Hepatocellular Carcinoma
Impact of Interferon Free Regimens in Patients With Chronic HCV and Successfully Treated HCC
The study will recruit 150 patients with HCV related HCC ,after HCC treatment the patients will undergo treatment with different regimens of DAAs.
- Trial name
- FRI-STC (NCT02771405)
- Testing
- Sofosbuvir, Ribavirin, Simeprevir
- Where
- Egypt
- Volunteers
- 150 people
- Sponsor
- National Hepatology & Tropical Medicine Research Institute